上海复星医药日前宣布，其控股子公司复星新药拟吸收合并及私有化港交所上市公司复宏汉霖，交易对价约为54亿港元。
礼德律师事务所为复星提供服务；富而德律师事务所代表复宏汉霖参与交易；凯易国际律师事务所则为财务顾问中金公司提供法律意见。
复宏汉霖是一家成立于2010年的生物制药公司，于2019年9月在港交所上市。复宏汉霖产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，已在中国上市5款产品，在国际获批上市3款产品。2023年，公司首次实现全年盈利。
富而德团队由合伙人Edward Freeman、黄颖慧、易卫忠牵头领导。
凯易团队由公司业务部合伙人周荔尔和倪豪领导，团队成员包括债务融资业务部合伙人郑蓓旎和张蒙。
Reed Smith, Freshfields, Kirkland on Henlius’ $691 mln take-private deal
Freshfields Bruckhaus Deringer is representing Hong Kong-listed biotech company Henlius on its $691 million take-private deal offer from Shanghai Fosun New Medicine Research Company, which is being advised by Reed Smith.
Kirkland & Ellis offered legal advice to the financial advisor, China International Capital Corporation (CICC), in the deal.
Henlius, established in 2010, was listed in Hong Kong in September 2019. Its product portfolio covers areas such as oncology, autoimmune diseases, and ophthalmic diseases. The company has launched five products in China and has three products approved for international markets. In 2023, the company achieved its first annual profit.
The Freshfields team was led by partners Edward Freeman, Grace Huang, and David Yi.
The Kirkland team was led by corporate partners Joey Chau and Nelson Ni, with assistance from debt finance partners Jacqueline Zheng and Sean Zhang.
